News

Clinical Advisor3h
RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
COVID ‘razor blade throat’ rises as new subvariant spreads in California
COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring 'razor ...